For example, SLFN11 may be a predictive biomarker to gemcitabine-based treatment regiments: the combination of gemcitabine with either WEE1i or ATRi may be an effective combination strategy in ovarian or pancreatic cancer where most tumours show a low or absent expression of SLFN11 (Fig. 1b). The gene discussed is SLFN11; the disease is pancreatic neoplasm.